Skip to main
  1. Stocks
  2. Ligand Pharmaceuticals
  3. Forecast
LGND

Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target

Ligand Pharmaceuticals (LGND) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ligand Pharmaceuticals is viewed positively because its high-margin royalty model keeps producing earnings beats, with Q3/26 revenue of $78.7MM and adjusted core EPS of $2.67 both topping estimates, while 2026 EPS guidance was raised to $9.50–$9.75 per share. Its investment case is further strengthened by the XOMA acquisition, which added 100+ programs, several commercial assets, and meaningful cost synergies, with management expecting operating expense to fall from about $25MM+ to just under $5MM and incremental EPS contribution in 2026 and 2027. The outlook is also supported by a deep catalyst pipeline, including priority review for Qtorin rapamycin with a Feb. 28, 2027 PDUFA date, strong Filspari royalty momentum, and more than $500MM in deployable capital to pursue accretive royalty deals.

Bears say

Ligand Pharmaceuticals is viewed negatively because its earnings are heavily exposed to royalty streams that could weaken if commercial products face stronger competition or slower sales, leaving little cash flow after Yr 10 in a downside case. Its dependence on Captisol adds another concentration risk, while manufacturing, IP, and strategic acquisition/integration failures could directly impair operations and shareholder value. The company’s pipeline and newly commercialized drugs also carry elevated clinical, regulatory, reimbursement, and patent risks, and if acquisitions or financing do not align with management’s targets, the stock could face additional downside.

Ligand Pharmaceuticals (LGND) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ligand Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Ligand Pharmaceuticals (LGND) Analyst Forecast & Price Prediction

Get the latest Ligand Pharmaceuticals (LGND) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Ligand Pharmaceuticals (LGND)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ligand Pharmaceuticals (LGND) Forecast

Analysts have given Ligand Pharmaceuticals (LGND) a Buy based on their latest research and market trends.

According to 8 analysts, Ligand Pharmaceuticals (LGND) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $355.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $355.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ligand Pharmaceuticals (LGND)


Ligand Pharmaceuticals (LGND) Analyst Forecast & Price Prediction

Get the latest Ligand Pharmaceuticals (LGND) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Ligand Pharmaceuticals (LGND)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover LGND stock data and trends